Komo Biosciences
3 known investors
KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies. The company was founded around record-breaking integrase technology for improving gene editing vectors.
Founders & leadership
JM
Jennifer ManningFounder & CEO
TP
Thomas PageActing CTO
MF
Matt FarabaughActing CFO
JB
Jesse B. OwensActing CSA
RT
Ray TabibiazarChairman of the Board